BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

...the past three weeks, FDA has added four companion diagnostic indications to the label of Foundation Medicine’s...
...compound #), AG-014699 (Former compound #), rucaparib (Generic) Alecensa, Alecensaro, alectinib (AF802, CH5424802, RG7853, RO5424802) Piqray, alpelisib (BYL719) Foundation Medicine Inc. Clovis...
BioCentury | Oct 28, 2020
Deals

Thrive takeout could herald consolidation trend for early cancer detection companies

...million series C round in August via its Roche Venture Fund. The fund also invested in Foundation Medicine Inc.’s...
BioCentury | Oct 2, 2020
Finance

Sophia aims to parlay expertise of new backers aMoon, Hitachi to grow biopharma business

...the way Guardant Health Inc. (NASDAQ:GH) and Foundation Medicine Inc....
BioCentury | Jul 15, 2020
Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

...of genomic profiling company Foundation Medicine Inc. prior to its acquisition by Roche (SIX:ROG; OTCQX:RHHBY) in 2018. Foundation Medicine...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

...successful launch and one that ensures the right patients get access to the therapy. “Through Foundation Medicine...
...“Success in Lung Cancer Niches Will Hinge on Access to Next-Gen Sequencing” ). Through Roche’s Foundation Medicine...
BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

...with a high mutational burden -- tumors with at least 10 mutations/megabase as assessed using Foundation Medicine Inc.’s...
BioCentury | May 6, 2020
Regulation

FDA approval of Novartis’ capmatinib heralds arrival of new targeted lung cancer therapies

...cancer patients with a certain c-MET mutation. Tabrecta and its FoundationOne CDx companion diagnostic from Foundation Medicine Inc....
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...who has served as interim CEO since September. Civik was chief commercial officer of the Foundation Medicine Inc....
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...Troy Cox will become chairman on March 1, succeeding Antoine Duchateau. Cox was CEO of Foundation Medicine Inc....
BioCentury | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

...Riley was VP, general manager of Catalent Biologics; Boerman was president of Aesica Pharmaceuticals Ltd. Foundation Medicine Inc....
...CRISPR-based gene therapies for eye diseases. BioCentury Staff Disarm Therapeutics Inc. Acacia Pharma Group plc Twist Bioscience Corp. Flatiron Health Inc. Foundation Medicine Inc. BioNTech...
Items per page:
1 - 10 of 238
BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

...the past three weeks, FDA has added four companion diagnostic indications to the label of Foundation Medicine’s...
...compound #), AG-014699 (Former compound #), rucaparib (Generic) Alecensa, Alecensaro, alectinib (AF802, CH5424802, RG7853, RO5424802) Piqray, alpelisib (BYL719) Foundation Medicine Inc. Clovis...
BioCentury | Oct 28, 2020
Deals

Thrive takeout could herald consolidation trend for early cancer detection companies

...million series C round in August via its Roche Venture Fund. The fund also invested in Foundation Medicine Inc.’s...
BioCentury | Oct 2, 2020
Finance

Sophia aims to parlay expertise of new backers aMoon, Hitachi to grow biopharma business

...the way Guardant Health Inc. (NASDAQ:GH) and Foundation Medicine Inc....
BioCentury | Jul 15, 2020
Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

...of genomic profiling company Foundation Medicine Inc. prior to its acquisition by Roche (SIX:ROG; OTCQX:RHHBY) in 2018. Foundation Medicine...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

...successful launch and one that ensures the right patients get access to the therapy. “Through Foundation Medicine...
...“Success in Lung Cancer Niches Will Hinge on Access to Next-Gen Sequencing” ). Through Roche’s Foundation Medicine...
BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

...with a high mutational burden -- tumors with at least 10 mutations/megabase as assessed using Foundation Medicine Inc.’s...
BioCentury | May 6, 2020
Regulation

FDA approval of Novartis’ capmatinib heralds arrival of new targeted lung cancer therapies

...cancer patients with a certain c-MET mutation. Tabrecta and its FoundationOne CDx companion diagnostic from Foundation Medicine Inc....
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...who has served as interim CEO since September. Civik was chief commercial officer of the Foundation Medicine Inc....
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...Troy Cox will become chairman on March 1, succeeding Antoine Duchateau. Cox was CEO of Foundation Medicine Inc....
BioCentury | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

...Riley was VP, general manager of Catalent Biologics; Boerman was president of Aesica Pharmaceuticals Ltd. Foundation Medicine Inc....
...CRISPR-based gene therapies for eye diseases. BioCentury Staff Disarm Therapeutics Inc. Acacia Pharma Group plc Twist Bioscience Corp. Flatiron Health Inc. Foundation Medicine Inc. BioNTech...
Items per page:
1 - 10 of 238